Last update 07 Jul 2026

Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.

Subsidiary Company|2021|Guangdong Sheng, China|
www.nkcbiotech.com

Overview

Tags

Hemic and Lymphatic Diseases
Neoplasms
Cell therapy

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Disease DomainCount
Hemic and Lymphatic Diseases1
Neoplasms1
Top 5 Drug TypeCount
Cell therapy1

Related

1
Drugs associated with Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
NKC007
Target-
Mechanism-
Active Org.
Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
Originator Org.
Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
Active Indication
Acute Myeloid Leukemia [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
CTR20261037
/ Not yet recruitingPhase 1
NKC007细胞注射液治疗急性髓系白血病患者的Ⅰ期临床试验
[Translation] Phase I clinical trial of NKC007 cell injection for the treatment of patients with acute myeloid leukemia
100 Clinical Results associated with Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Guangzhou Anthracite Kaisai Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
NKC007
Relapsing acute myeloid leukemia
More
IND Approval
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free